Johnson & Johnson Past Earnings Performance

Past criteria checks 6/6

Johnson & Johnson has been growing earnings at an average annual rate of 0.3%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 2.7% per year. Johnson & Johnson's return on equity is 27.9%, and it has net margins of 22.4%.

Key information

0.3%

Earnings growth rate

1.1%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	2.7%
Return on equity	27.9%
Net Margin	22.4%
Next Earnings Update	17 Jul 2024

Recent past performance updates

Recent updates

Johnson & Johnson (NYSE:JNJ) Will Pay A Larger Dividend Than Last Year At $1.24

Apr 19

Johnson & Johnson: Buy This Bargain Before It's Gone

Apr 18

Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds

Apr 11

Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'

Jan 25

Revenue & Expenses Breakdown
Beta

How Johnson & Johnson makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:JNJ Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 24	85,648	19,171	20,520	15,186
31 Dec 23	85,159	13,326	20,166	15,085
01 Oct 23	98,656	13,992	24,268	14,783
02 Jul 23	97,301	13,993	23,853	14,821
02 Apr 23	96,263	12,724	23,753	14,704
01 Jan 23	79,990	16,370	19,078	14,135
02 Oct 22	84,855	17,879	21,037	15,145
03 Jul 22	88,197	17,236	22,197	15,082
03 Apr 22	94,880	19,830	24,430	14,998
02 Jan 22	78,740	17,801	19,506	14,277
03 Oct 21	91,446	17,880	23,364	14,026
04 Jul 21	89,190	17,767	22,852	13,444
04 Apr 21	84,214	15,115	21,817	12,757
03 Jan 21	82,584	14,714	21,731	12,159
27 Sep 20	80,856	16,986	21,681	11,359
28 Jun 20	80,503	15,185	21,625	11,118
29 Mar 20	82,729	17,166	22,185	11,077
29 Dec 19	82,059	15,119	21,885	11,355
29 Sep 19	81,706	14,151	21,957	11,347
30 Jun 19	81,325	16,332	22,191	11,256
31 Mar 19	81,593	14,679	22,437	11,229
30 Dec 18	81,581	15,297	22,540	10,775
30 Sep 18	81,382	1,542	22,454	11,194
01 Jul 18	80,684	1,372	22,300	11,271
01 Apr 18	78,693	1,245	21,758	10,928
31 Dec 17	76,450	1,300	21,520	10,594
01 Oct 17	74,361	15,827	20,600	9,591
02 Jul 17	72,531	16,335	20,012	9,184
02 Apr 17	72,174	16,505	20,020	9,152
01 Jan 17	71,890	16,540	19,793	9,143
02 Oct 16	71,595	15,941	20,527	9,319
03 Jul 16	70,877	15,027	20,836	9,295
03 Apr 16	70,182	15,546	21,044	9,160
03 Jan 16	70,074	15,409	21,203	9,046
27 Sep 15	70,517	14,715	21,134	8,817
28 Jun 15	71,882	16,106	21,521	8,686
29 Mar 15	73,590	15,916	21,618	8,562
28 Dec 14	74,331	16,323	21,954	8,494
28 Sep 14	74,232	17,321	22,049	8,270
29 Jun 14	73,340	15,554	21,895	8,289
30 Mar 14	71,722	15,061	21,790	8,230
29 Dec 13	71,312	13,831	21,830	8,183
29 Sep 13	70,515	12,879	21,574	8,103
30 Jun 13	69,992	12,865	21,488	7,984

Quality Earnings: JNJ has high quality earnings.

Growing Profit Margin: JNJ's current net profit margins (22.4%) are higher than last year (13.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: JNJ's earnings have grown by 0.3% per year over the past 5 years.

Accelerating Growth: JNJ's earnings growth over the past year (49.7%) exceeds its 5-year average (0.3% per year).

Earnings vs Industry: JNJ earnings growth over the past year (49.7%) exceeded the Pharmaceuticals industry -6.8%.

Return on Equity

High ROE: JNJ's Return on Equity (27.9%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Johnson & Johnson Past Earnings Performance

Past criteria checks 6/6

Key information

Recent past performance updates

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Johnson & Johnson to Report Q2, 2024 Results on Jul 17, 2024

Full year 2023 earnings: EPS misses analyst expectations

Recent updates

Johnson & Johnson (NYSE:JNJ) Will Pay A Larger Dividend Than Last Year At $1.24

First quarter dividend increased to US$1.24

Johnson & Johnson: Buy This Bargain Before It's Gone

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Johnson & Johnson Revises Earnings Guidance for the Full Year of 2024

Johnson & Johnson Announces Planned Presentation of New Non-Clinical Studies

Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds

Johnson & Johnson Announces New Analysis of Data from the PionEER AF-PCI Clinical Trial Demonstrating XARELTO®? (rivaroxaban)

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson to Showcase its Latest Innovations to Combat Cardiovascular Disease at ACC.24

With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Opsynvi as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension

Johnson & Johnson Announces U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Recommends Carvykti®? (Ciltacabtagene Autoleucel) for the Early Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Insider recently sold US$1.4m worth of stock

Johnson & Johnson, Annual General Meeting, Apr 25, 2024

Johnson & Johnson to Report Q2, 2024 Results on Jul 17, 2024

Johnson & Johnson Announces the First Data from FRONTIER 2, the Long-Term Extension of the Phase 2b FONTIER 1 Clinical Trial Evaluating JNJ-2113

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Ambrx Biopharma Inc. (NasdaqGS:AMAM) from a group of shareholders.

Johnson & Johnson: A Clean Bill Of Health

Johnson & Johnson Announces the U.S. Food and Drug Administration Approves the Supplemental Biologics License Application for TECVAYLI®?

Is There An Opportunity With Johnson & Johnson's (NYSE:JNJ) 43% Undervaluation?

Insider notifies of intention to sell stock

Johnson & Johnson: A High-Quality Dividend King Facing Furious Headwinds

Upcoming dividend of US$1.19 per share at 3.0% yield

Johnson & Johnson Announces Publication in the New England Journal of Medicine of the Phase 2b FRONTIER 1 Trial Results for JNJ-2113

Johnson & Johnson Reports Positive Topline Results for Nipocalimab from Phase 3 Pivotal Study in Generalized Myasthenia Gravis and Phase 2 Study in Sjögren's Disease

Johnson & Johnson Submits Supplemental Biologics License Application to U.S. FDA Seek Approval of DARZALEX FASPRO

Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'

Johnson & Johnson Announces New Clinical and Real-World Evidence Data Will Be Featured in 18 Abstracts at This Year's ASCO GU Symposium

Full year 2023 earnings: EPS misses analyst expectations

Johnson & Johnson Provides Sales Guidance for the Full Year of 2024

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta